SWATH® Acquisition Improves Metabolite Coverage over Traditional Data Dependent Techniques for Untargeted Metabolomics

**A Data Independent Acquisition Technique Employed on the TripleTOF® 6600 System**

Zuzana Demianova¹; Cyrus Papan¹; Joerg Dojahn¹; Baljit K. Ubhi²
¹SCIEX, Darmstadt, Germany; ²SCIEX, Redwood City, CA

**Introduction**

SWATH® acquisition, a data independent acquisition (DIA) workflow is well adopted in quantitative discovery proteomics¹, but still not commonly used in discovery metabolomics. Traditional data dependent acquisition (DDA) techniques are heavily employed in the field of metabolomics and workflows on the mass spectrometers have been adapted so that as much data as possible can be captured. This has led to a two-injection workflow in the community; one injection to collect the MS and mine the data and a second for the MSMS to confirm the metabolite identification. Researchers were limited by the speed of their QTOF mass spectrometers because they could not scan fast enough to capture the data in a single injection. Also, the stochastic nature of data dependent workflows often means MSMS of low abundant metabolites are often missed. The TripleTOF® 6600 System allows both the MS and MSMS data to be collected in a single injection allowing you to build a digitized map of every detectable metabolite in your sample - meaning no need to go back and re-run your sample but just re-mine the data as your hypothesis changes. Here, we describe how SWATH® acquisition enables the identification of a higher number of metabolites for untargeted metabolomics workflows² compared to traditional data dependent acquisition (DDA) approaches thus enabling a broader profile of the metabolome³. Our results show that SWATH acquisition using variable windows improves metabolite coverage using the Accurate Mass Metabolite Spectral Library (AMMSL) compared with the traditional DDA approach.

**Benefits of the SWATH® Acquisition Workflow for Metabolomics Applications**

1. Full scan (MS1) and MSMS of every single metabolite in your sample in a single injection
2. Comprehensive identification and quantitation of the metabolites in your sample
3. No method development required
4. Permanent digital record of the metabolome of your sample
5. Narrower Q1 isolation windows provide improved data quality through increased specificity³
6. SWATH Variable Window Calculator⁴ can be used to optimize the Q1 isolation window pattern for the matrix of interest, to achieve the right balance of metabolite coverage and specificity.

---

**Gain in Metabolite Coverage in Plasma Extracts.** Over 55% gain in metabolite coverage with SWATH® acquisition with 20 variable width windows over top20 DDA acquisition.
Experimental Section

Human urine and commercially available human plasma were processed according to standard extraction protocols. Urine was diluted with water at a ratio of 1:4 (v/v) and centrifuged for prior analysis, whilst plasma was extracted 1:4 (v/v) with ice-cold methanol allowing for protein precipitation. Separation was performed on an Agilent Technologies 1290 Infinity II using an Acquity BEH C18 column with dimensions; 100mm x 2.1 mm ID, 1.7 µm (Waters, Milford, USA) using a flow rate 200 µl/min. A gradient was employed from 1-10 minutes from 2-98% of 0.1% formic acid in acetonitrile, total length of LC separation was 14 minutes and column oven temperature was set to 40°C. Injection volume was 5 µl for both type of samples.

Mass Spectrometry settings were as follows: Curtain Gas 35 psi, GS1 40 psi, GS2 40 psi, ISVF 5500 V, Source temp. 600°C, Declustering Potential 80 V and additional in MS/MS mode collision energy was 30 V with 15 V spread. Data dependent and SWATH acquisition specific settings were chosen as listed in Table 1. The data was collected in positive mode.

The SWATH® acquisition and DDA experiments were acquired on a TripleTOF® 6600 System. Data was processed using MasterView™ Software version 1.1 and the Accurate Mass Metabolite Spectral Library (AMMSL) using search settings accordingly: candidate search algorithm, results sorted by Purity (for DDA data) or Fit (for SWATH acquisition data). A combined score (isotope distribution pattern, fragmentation pattern, mass error) of >70% was used to evaluate the confidence in the metabolite identification.

For the DDA acquisition, we selected the top 5, 10, 15, 20 and 25 precursor ions for MSMS, described hereon in as top5, top10, top15, top 20 and top25 (Table 1). For SWATH® acquisition, we applied 15, 20 and 30 SWATH windows with either fixed window (fw) or variable window (vw) widths; described hereon in as fw15, fw20, fw30, vw15, vw20 and vw30. All these settings were used to test which parameters resulted in the highest number of identifications and coverage of metabolites in plasma and urine extracts (Table 2).

The Top20 DDA acquisition method was used to calculate variable windows using a SWATH Variable Window Assay

Figure 1. Variable Q1 Window Widths Explored across Sample Matrices. To achieve better specificity in complex matrices, smaller Q1 windows are desirable especially in the m/z dense regions where many analyte precursors are found. The m/z density histograms constructed from the TOF MS data for the sample of interest (blue line) can be used to a construct variable sized window pattern (red line) using the SWATH Variable Window Calculator. The goal is to equalize the density of precursors in each of the isolation windows across the m/z range. A) A urine sample with 15 variable windows (vw) and B) with vw30 highlighting more specificity through smaller Q1 windows in the densest regions of the data; C) A plasma sample with vw15 and D) with vw30.
Results and Discussion

In the first part of our study, we evaluated the traditional DDA acquisition strategy by comparing the number of precursors selected for MSMS analysis. We used identical accumulation time of 25ms across these DDA experiments to be able to compare the data. We evaluated the coverage of these different methods by matching the metabolites to the spectral library (AMMSL) which contains over 550 exogenous and endogenous metabolites to a human plasma extract (Figure 2). A library score of 70% and above was used as the cutoff criteria for a high quality confirmed metabolite match.

The data demonstrate a significant improvement of metabolite coverage at the MSMS level when comparing the top5 to the top25 DDA method (Figure 2). In Figure 2, we show over 100% increase of metabolite coverage in plasma extracts by increasing the number of selected precursor ions for DDA acquisition from top5 to top25. This result highlights the capability of the TripleTOF 6600 system for fast MSMS acquisition, which allows for the fragmentation of a large number of precursors in a single DDA cycle, leading to a larger number of metabolites identified.

Table 1. Experimental Comparison. Top: DDA acquisition MS method settings. Bottom: SWATH® acquisition MS settings for fixed windows (fw) and variable windows (vw) size.

<table>
<thead>
<tr>
<th>DDA acquisition</th>
<th>Top 5</th>
<th>Top 10</th>
<th>Top 15</th>
<th>Top 20</th>
<th>Top 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nr. precursor ions</td>
<td>5</td>
<td>10</td>
<td>15</td>
<td>20</td>
<td>25</td>
</tr>
<tr>
<td>TOF MS range/Da</td>
<td>100-500</td>
<td>100-500</td>
<td>100-500</td>
<td>100-500</td>
<td>100-500</td>
</tr>
<tr>
<td>MS Acc. time/ms</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>TOF MSMS range/Da</td>
<td>50-500</td>
<td>50-500</td>
<td>50-500</td>
<td>50-500</td>
<td>50-500</td>
</tr>
<tr>
<td>MSMS Acc. time/ms</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Cycle time/ms</td>
<td>225</td>
<td>350</td>
<td>475</td>
<td>600</td>
<td>725</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SWATH® acquisition</th>
<th>Fixed Windows</th>
<th>Variable Windows</th>
</tr>
</thead>
<tbody>
<tr>
<td>fw15</td>
<td>fw20</td>
<td>fw30</td>
</tr>
<tr>
<td>Nr. SWATH® windows</td>
<td>15</td>
<td>20</td>
</tr>
<tr>
<td>Window size/Da</td>
<td>26</td>
<td>19</td>
</tr>
<tr>
<td>TOF MS range/Da</td>
<td>100-500</td>
<td>100-500</td>
</tr>
<tr>
<td>MS Acc. time/ms</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>TOF MSMS range/Da</td>
<td>50-500</td>
<td>50-500</td>
</tr>
<tr>
<td>MSMS Acc. time/ms</td>
<td>30</td>
<td>25</td>
</tr>
<tr>
<td>Cycle time/ms</td>
<td>550</td>
<td>600</td>
</tr>
</tbody>
</table>

In the second part of this study, we evaluated the SWATH® acquisition strategy with various fixed (fw) and variable window (vw) sizes with similar cycle time in a plasma extract. As shown in Figure 3, increasing the number of fixed windows resulted in ~30% gain in metabolite coverage. Using the variable window method resulted in a ~70% gain in metabolite coverage.

Figure 2. Evaluating the DDA Strategy for Untargeted Metabolomics Workflows. Gain in metabolite coverage in a plasma extract using various DDA acquisition methods with constant acquisition time above the Top5 DDA method. There is over 100% increase of metabolite coverage in plasma extracts by increasing the number of selected precursor ions for DDA acquisition from top5 to top25.

Figure 3. Evaluating the DIA Strategy for Untargeted Metabolomics Workflows. Gain in metabolite coverage in a plasma extract using various SWATH® acquisition approaches with constant cycle time. Increasing the number of windows selected for SWATH® acquisition resulted in ~30% gain in metabolite coverage using fixed windows (blue) and ~70% gain in plasma extracts using the variable windows (red) strategy.

These results show that decreasing the window size and varying the window size, depending on the precursor ion mass density, improves the overall ion selectivity as shown in Figure 4. This
highlights an example of the MSMS spectrum of D-Lysine with a precursor mass 147.1125 m/z. Here one can visualize a Q1 window from 127.1-149.4 m/z (top) and Q1 window from 137.7-149.4 m/z (bottom) acquired using a SWATH acquisition method with 15 variable windows and 30 variable windows, respectively. Figure 3 (top panel) clearly show many fragments from other co-eluting metabolites infiltrating the MSMS spectrum within the mass range from 127.1 m/z to 149.4 m/z. This highlights the need for a higher number of SWATH windows with narrower widths, allowing fewer precursor ions selected for MSMS fragmentation, resulting in higher specificity and selectivity, necessary for confident metabolite identification.

Figure 4. The SWATH Acquisition Variable Windows Effect on Fragmentation Spectra in Plasma Extract. Fragmentation spectra for a metabolite, D-Lysine highlighting the comparison between 15 (top) and 30 (bottom) variable windows with a cycle time ~0.6 seconds in plasma extract. The blue spectrum represents all measured MSMS ions and the grey spectrum shows the library spectrum of D-Lysine from the Accurate Mass Metabolite Spectral Library. It can be observed that a higher number of Q1 windows allows for cleaner data and hence leads to a higher specificity resulting in a higher quality spectral match to the library.

In the third step, we compared the identification rate between SWATH acquisition and traditional DDA acquisition in a plasma extract. At first glance DDA acquisition presents a higher number of metabolites identified solely based at the MS1 level (Figure 5, MS acquired); however when the MSMS is used to confirm the metabolites, the numbers of identified metabolites drops significantly; most likely due to the sheer number of false positives using just the MS1 data (and mass accuracy alone). These numbers drop further when the library score is set to 70% and above meaning that the MS1, MSMS, isotope distribution and retention time must have a combined scoring of 70% and above to be considered a high level identification (Figure 5).

The SWATH acquisition method is using information obtained from both the MS and MSMS spectrum. Due to this, metabolites are identified not only on their exact mass, but also based on their molecular structure. Figure 5 also shows an increased number of metabolites identified at the MSMS level for samples measured using SWATH acquisition.

We finally applied these experimental approaches to common matrices used in metabolomics studies, namely urine and extracted plasma. Figure 6 (top) illustrates that SWATH acquisition applying 20 variable windows can identify up to 55% more metabolites than a traditional top20 DDA acquisition (in a urine extract). More confident MSMS based identifications lead to higher quantifiable metabolites in a metabolite expression experiment, which at the end allows better understanding of the biology. When comparing the performance in extracted plasma it can be observed that applying SWATH acquisition with 20 variable windows allows significant gains in metabolite coverage (around 55%) versus the top20 DDA acquisition, similar gains as seen in the urine extract (Figure 6 bottom).

Lastly note to the user that the larger the library the more coverage one can gain from a sample. The library used for these
experiments even though small in size, contained high quality TripleTOF-generated spectra from biochemically relevant metabolites.

metabolite identification was shown using the Accurate Mass Metabolite Spectral Library when employing variable window SWATH® acquisition compare to traditional DDA acquisition.

Using variable windows instead of fixed windows significantly improved the metabolite coverage.

Increasing the number of windows will refine the quality of the MSMS spectra, thereby increasing the selectivity, and yield higher quality metabolite identifications.

Setting up the correct Q1 window width can be curial when measuring different matrixes.

Furthermore, the advantages of SWATH acquisition allow no method development by employing a generic method setup. Generate a digitized map of your samples metabolome and never re-run a sample ever again, just re-mine the data collected!

Figure 6. Gain in Metabolite Coverage in Urine and Plasma Extracts. Top: 55% gain in metabolite coverage with top20 DDA and vw20 SWATH® acquisition in human urine. Graph is normalized to the highest library coverage, SWATH® acquisition with 20 variable windows. Bottom: Over 55% gain in metabolite coverage with top20 DDA and vw20 SWATH® acquisition in human plasma. Graph is normalized to the highest library coverage, SWATH® acquisition with 20 variable windows. For comparison, methods with the same MSMS accumulation of 25 ms were used.

Conclusions

Over 50% gain in metabolite coverage and greater MSMS level

References


3. Improved Data Quality Using Variable Q1 Window Widths in SWATH® Acquisition, SCIEX Technical Note, RUO-MKT-02-2879-B


AB Sciex is doing business as SCIEX.

© 2017 AB Sciex. For Research Use Only. Not for use in diagnostic procedures. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEX™ is being used under license.

Document number: RUO-MKT-02-7128A